Novocure Ltd Ord Sh (NVCR)

$13.12 +0.19 (1.47%)
Market Cap 1.47B
Revenue (ttm) 605.22M
Net Income (ttm) -168.63M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -27.86%
Debt to Equity Ratio 0.57
Volume 1,714,300
Avg Vol 1,625,282
Day's Range N/A - N/A
Shares Out 111.98M
Stochastic %K 38%
Beta 0.73
Analysts Strong Sell
Price Target $25.21

Company Profile

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic ca...

Industry: Medical Devices
Sector: Healthcare
Address:
Neuhofstrasse 21, Baar, Switzerland
Kyle7776
Kyle7776 Jan. 4 at 12:10 PM
$NVCR run to 20 or more with positive panova 4 data?
0 · Reply
GordonGecko_was_THE_MAN
GordonGecko_was_THE_MAN Jan. 3 at 8:35 PM
$NVCR (1/n) Science geeks: for a long time skeptics have asked exactly how TTFs work? Most who follow the story understand alternating fields re-orient the polar molecules required for the cell division, thus preventing proper division. However, we now have lots of data saying TTFs + IO is synergistic, that TTFs turn cold tumors hot. New GROUNDBREAKING paper from Prof. Palti (TTF inventor) now provides incredible explanation. https://www.mdpi.com/1422-0067/26/24/12086
1 · Reply
scotofool
scotofool Jan. 2 at 2:55 PM
$NVCR mates, welcome 2026 year reckoning $NVCR conjob. Charlottan CEO bilked millions, tekkie don't work, data fudgy. Racket up, investors know user doccies no use. target 7.
1 · Reply
JuggernautRaider
JuggernautRaider Jan. 2 at 3:48 AM
$NVCR $JFBR $NUKK $KPTI all hit hard by targeted short selling due to Israel’s many issues and poised for better times ahead ⏰
0 · Reply
Tdorsey1776
Tdorsey1776 Jan. 1 at 12:36 AM
$NVCR Novocure to outperform the market in 2026.... time to look forward not back.
2 · Reply
GordonGecko_was_THE_MAN
GordonGecko_was_THE_MAN Dec. 29 at 10:47 PM
$NVCR seeing a bunch of clearly AI bot driven comments on this board of late. Perhaps this is a sign of more interest in NVCR? or maybe just ST has a problem with bots. are people seeing this on other boards as well?
1 · Reply
ConvergenceCharm
ConvergenceCharm Dec. 27 at 5:41 PM
$NVCR Market participants want evidence that strategy converts to numbers; cost controls have to translate into healthier margins — proving resilience would extend investor horizons. In the end, repeatable performance earns the premium.
1 · Reply
CapitalCallC
CapitalCallC Dec. 27 at 9:35 AM
$NVCR Risk tolerance remains selective and tied closely to execution credibility. Governance alignment can reduce perceived uncertainty. Transparency improvements could narrow valuation spreads. Ultimately, disciplined delivery will shape the outcome.
0 · Reply
GoBigRed19
GoBigRed19 Dec. 27 at 1:41 AM
$NVCR
0 · Reply
scotofool
scotofool Dec. 24 at 4:46 PM
to all the knowledge wankers pumping this turdy, piss off. yous not helping patient, $NVCR proper trash. datas overegged pudding. CEO muppet twit. target 7. merry xmas
0 · Reply
Latest News on NVCR
NovoCure: 2026 Pipeline Outlook Makes This Stock A Speculative Buy

Jan 2, 2026, 6:44 AM EST - 2 days ago

NovoCure: 2026 Pipeline Outlook Makes This Stock A Speculative Buy

Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 22, 2025, 7:00 AM EST - 13 days ago

Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference

Novocure Appoints Company President Frank Leonard as Chief Executive Officer

Dec 1, 2025, 7:00 AM EST - 4 weeks ago

Novocure Appoints Company President Frank Leonard as Chief Executive Officer

Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference

Nov 26, 2025, 7:00 AM EST - 5 weeks ago

Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference

Novocure to Participate in 2025 Jefferies Global Healthcare Conference

Nov 12, 2025, 7:00 AM EST - 7 weeks ago

Novocure to Participate in 2025 Jefferies Global Healthcare Conference

NovoCure Limited (NVCR) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 3:16 PM EDT - 2 months ago

NovoCure Limited (NVCR) Q3 2025 Earnings Call Transcript

Novocure Reports Third Quarter 2025 Financial Results

Oct 30, 2025, 7:00 AM EDT - 2 months ago

Novocure Reports Third Quarter 2025 Financial Results

NovoCure: Buy Rating As Pipeline Gains Drive Renewed Momentum

Oct 17, 2025, 7:55 AM EDT - 2 months ago

NovoCure: Buy Rating As Pipeline Gains Drive Renewed Momentum

Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress

Oct 15, 2025, 7:00 AM EDT - 2 months ago

Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress

Novocure to Report Third Quarter 2025 Financial Results

Oct 1, 2025, 7:00 AM EDT - 3 months ago

Novocure to Report Third Quarter 2025 Financial Results

Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting

Sep 29, 2025, 4:30 PM EDT - 3 months ago

Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting

Novocure's Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)

Sep 15, 2025, 7:00 AM EDT - 4 months ago

Novocure's Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)

NovoCure Limited (NVCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 10, 2025, 5:53 PM EDT - 4 months ago

NovoCure Limited (NVCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Novocure Announces Upcoming Investor Events

Aug 28, 2025, 7:00 AM EDT - 4 months ago

Novocure Announces Upcoming Investor Events

Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain

Aug 25, 2025, 7:00 AM EDT - 4 months ago

Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain

Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer

Aug 20, 2025, 7:00 AM EDT - 4 months ago

Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer

NovoCure's Wearable Oncology Edge And Compelling Valuation

Jul 30, 2025, 12:47 AM EDT - 5 months ago

NovoCure's Wearable Oncology Edge And Compelling Valuation

Top 3 Health Care Stocks That May Explode In July

Jul 28, 2025, 6:52 AM EDT - 5 months ago

Top 3 Health Care Stocks That May Explode In July

HCA MOH

NovoCure Limited (NVCR) Q2 2025 Earnings Call Transcript

Jul 25, 2025, 4:49 PM EDT - 5 months ago

NovoCure Limited (NVCR) Q2 2025 Earnings Call Transcript

Novocure Reports Second Quarter 2025 Financial Results

Jul 24, 2025, 7:00 AM EDT - 5 months ago

Novocure Reports Second Quarter 2025 Financial Results

Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025

Jul 1, 2025, 7:00 AM EDT - 6 months ago

Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025

Novocure to Report Second Quarter 2025 Financial Results

Jun 30, 2025, 7:00 AM EDT - 6 months ago

Novocure to Report Second Quarter 2025 Financial Results

NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial

Jun 2, 2025, 2:05 PM EDT - 7 months ago

NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

May 31, 2025, 3:08 PM EDT - 7 months ago

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

ZLAB

Results From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

May 31, 2025, 8:00 AM EDT - 7 months ago

Results From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

NovoCure: Loading Up On Growth Catalysts

May 24, 2025, 3:12 AM EDT - 8 months ago

NovoCure: Loading Up On Growth Catalysts

NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025

Apr 24, 2025, 12:39 PM EDT - 9 months ago

NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025

NovoCure Limited (NVCR) Q1 2025 Earnings Call Transcript

Apr 24, 2025, 10:34 AM EDT - 9 months ago

NovoCure Limited (NVCR) Q1 2025 Earnings Call Transcript

Novocure Reports First Quarter 2025 Financial Results

Apr 24, 2025, 7:00 AM EDT - 9 months ago

Novocure Reports First Quarter 2025 Financial Results

Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting

Apr 23, 2025, 10:16 AM EDT - 9 months ago

Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting

Novocure's Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer

Apr 22, 2025, 7:09 AM EDT - 9 months ago

Novocure's Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer

Novocure to Report First Quarter 2025 Financial Results

Apr 1, 2025, 7:00 AM EDT - 9 months ago

Novocure to Report First Quarter 2025 Financial Results

Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference

Mar 4, 2025, 7:00 AM EST - 10 months ago

Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference

NovoCure Q4 2024 Earnings: Strong And Growing Pipeline

Feb 28, 2025, 1:10 PM EST - 11 months ago

NovoCure Q4 2024 Earnings: Strong And Growing Pipeline

NovoCure's Expansion Strategy Struggles To Translate Approvals Into Growth

Feb 28, 2025, 5:17 AM EST - 11 months ago

NovoCure's Expansion Strategy Struggles To Translate Approvals Into Growth

NovoCure Limited (NVCR) Q4 2024 Earnings Conference Call Transcript

Feb 27, 2025, 9:09 AM EST - 11 months ago

NovoCure Limited (NVCR) Q4 2024 Earnings Conference Call Transcript

Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

Feb 27, 2025, 7:00 AM EST - 11 months ago

Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland

Jan 22, 2025, 4:00 AM EST - 1 year ago

Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland

Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update

Jan 13, 2025, 7:00 AM EST - 1 year ago

Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update

Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference

Jan 3, 2025, 7:00 AM EST - 1 year ago

Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference

NovoCure: PANOVA-3 Data Suggests A Potential Game-Changer For Pancreatic Cancer

Dec 4, 2024, 9:59 PM EST - 1 year ago

NovoCure: PANOVA-3 Data Suggests A Potential Game-Changer For Pancreatic Cancer

Novocure Moves Pancreatic Cancer Treatment Forward With A 'First' Using TTFields

Dec 2, 2024, 1:10 PM EST - 1 year ago

Novocure Moves Pancreatic Cancer Treatment Forward With A 'First' Using TTFields

NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients

Dec 2, 2024, 10:12 AM EST - 1 year ago

NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients

Novocure's pancreatic cancer treatment meets main goal in late-stage study

Dec 2, 2024, 7:17 AM EST - 1 year ago

Novocure's pancreatic cancer treatment meets main goal in late-stage study

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

Dec 2, 2024, 7:02 AM EST - 1 year ago

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

ZLAB

Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

Dec 2, 2024, 7:00 AM EST - 1 year ago

Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

Novocure to Participate in Upcoming Investor Conferences

Nov 27, 2024, 7:00 AM EST - 1 year ago

Novocure to Participate in Upcoming Investor Conferences

Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma

Nov 21, 2024, 7:05 AM EST - 1 year ago

Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma

FDA Approves Novocure's Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma

Nov 21, 2024, 7:00 AM EST - 1 year ago

FDA Approves Novocure's Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma

NovoCure Limited (NVCR) Q3 2024 Earnings Conference Call Transcript

Oct 30, 2024, 11:53 AM EDT - 1 year ago

NovoCure Limited (NVCR) Q3 2024 Earnings Conference Call Transcript

Kyle7776
Kyle7776 Jan. 4 at 12:10 PM
$NVCR run to 20 or more with positive panova 4 data?
0 · Reply
GordonGecko_was_THE_MAN
GordonGecko_was_THE_MAN Jan. 3 at 8:35 PM
$NVCR (1/n) Science geeks: for a long time skeptics have asked exactly how TTFs work? Most who follow the story understand alternating fields re-orient the polar molecules required for the cell division, thus preventing proper division. However, we now have lots of data saying TTFs + IO is synergistic, that TTFs turn cold tumors hot. New GROUNDBREAKING paper from Prof. Palti (TTF inventor) now provides incredible explanation. https://www.mdpi.com/1422-0067/26/24/12086
1 · Reply
scotofool
scotofool Jan. 2 at 2:55 PM
$NVCR mates, welcome 2026 year reckoning $NVCR conjob. Charlottan CEO bilked millions, tekkie don't work, data fudgy. Racket up, investors know user doccies no use. target 7.
1 · Reply
JuggernautRaider
JuggernautRaider Jan. 2 at 3:48 AM
$NVCR $JFBR $NUKK $KPTI all hit hard by targeted short selling due to Israel’s many issues and poised for better times ahead ⏰
0 · Reply
Tdorsey1776
Tdorsey1776 Jan. 1 at 12:36 AM
$NVCR Novocure to outperform the market in 2026.... time to look forward not back.
2 · Reply
GordonGecko_was_THE_MAN
GordonGecko_was_THE_MAN Dec. 29 at 10:47 PM
$NVCR seeing a bunch of clearly AI bot driven comments on this board of late. Perhaps this is a sign of more interest in NVCR? or maybe just ST has a problem with bots. are people seeing this on other boards as well?
1 · Reply
ConvergenceCharm
ConvergenceCharm Dec. 27 at 5:41 PM
$NVCR Market participants want evidence that strategy converts to numbers; cost controls have to translate into healthier margins — proving resilience would extend investor horizons. In the end, repeatable performance earns the premium.
1 · Reply
CapitalCallC
CapitalCallC Dec. 27 at 9:35 AM
$NVCR Risk tolerance remains selective and tied closely to execution credibility. Governance alignment can reduce perceived uncertainty. Transparency improvements could narrow valuation spreads. Ultimately, disciplined delivery will shape the outcome.
0 · Reply
GoBigRed19
GoBigRed19 Dec. 27 at 1:41 AM
$NVCR
0 · Reply
scotofool
scotofool Dec. 24 at 4:46 PM
to all the knowledge wankers pumping this turdy, piss off. yous not helping patient, $NVCR proper trash. datas overegged pudding. CEO muppet twit. target 7. merry xmas
0 · Reply
Tdorsey1776
Tdorsey1776 Dec. 24 at 3:04 PM
$NVCR $VRDN $CAPR $TMDX Its a been a pretty excellent year in bio land, and there's much more to come in 2026 and beyond. Feeling especially appreciative; made a large contribution to St. Jude's. Please dont forget all they do for little kids who dont desrve to be stricken at such a young age and the familes living through the misery. Merry Christmas all.
1 · Reply
GeneticGains
GeneticGains Dec. 24 at 11:06 AM
$NVCR The longer-term setup revolves around whether timelines compress uncertainty rather than extend speculation. Sustained traction would support a meaningful re-rating.
1 · Reply
justiceforb_85
justiceforb_85 Dec. 23 at 4:47 AM
$NVCR when is the next update--FDA submission this quarter?
0 · Reply
CCrazy1990
CCrazy1990 Dec. 22 at 5:16 PM
$NVCR Question for the group: what would a positive PANOVA 4 data readout look like to you?
1 · Reply
DingDong9
DingDong9 Dec. 18 at 4:05 PM
$NVCR one of my top picks for 2026
0 · Reply
QuantitativeTrading_
QuantitativeTrading_ Dec. 18 at 12:59 PM
Brain-computer interface boom starting, most watch Neuralink — supply chain richer. Gold rush: shovel sellers. BCI "picks and shovels": $MDT: Medical devices $ABT: Neuro tech $SEM: Electrode materials $NVCR: Brain therapy $ISRG: Precision tools
0 · Reply
Czm514
Czm514 Dec. 16 at 3:25 PM
$NVCR Frank, how about a PR with some good news? Give those Israeli gangsters something to pump. Bag holders getting very weary. Down 57% YTD
1 · Reply
neilyoungsband
neilyoungsband Dec. 15 at 8:30 PM
$NVCR going under a dollar in 6 months....
1 · Reply
scotofool
scotofool Dec. 15 at 2:31 PM
$NVCR sure mate $NVCR 2026 boffins roasting noggins dead, proper trash, target 7
0 · Reply
Tdorsey1776
Tdorsey1776 Dec. 15 at 1:30 PM
$NVCR Its cold outside people, but feels like Novocure is getting ready to heat up in 2026. GLTA
0 · Reply
TommBa
TommBa Dec. 11 at 10:30 PM
$NWBO will it seems someone is worried about what is coming. Look who shows up for me on Google as a sponsored result when I searched for dcvax. Note: I am based in Spain at the moment, which is why $NVCR is showing .es
0 · Reply
scotofool
scotofool Dec. 11 at 4:41 PM
$NVCR @RudeYak wanker, price ridings markets, wait bottoms, looky history. trashy device, pisspoor leaders, falsified datas, proper cock-up. target 7
1 · Reply